New Guidelines Recommend Daily HIV Prevention Pill for Those at Substantial Risk

May 14, 2014 - New Guidelines Recommend Daily HIV Prevention Pill for Those at Substantial Risk

New clinical guidelines recommend that health care providers consider pre-exposure prophylaxis (PrEP) for patients at substantial risk for HIV. PrEP is the use of anti-HIV drugs by people who do not have HIV to reduce the risk of infection.

For your stories about the new guidelines, please find below a press release – which provides key facts about PrEP and also outlines the specific indications for which PrEP is recommended – as well as other useful background resources on HIV.

Resources

Press Release: New Guidelines Recommend Daily HIV Prevention Pill for Those at Substantial Risk
Guidelines: Preexposure Prophylaxis for the Prevention of HIV Infection in the United States–2014: A Clinical Practice Guideline
Providers' Supplement: Preexposure Prophylaxis for the Prevention of HIV Infection in the United States–2014: Clinical
Providers’ Supplement
Background Materials
- Background Information about PrEP
- Fact Sheets:
  - PrEP: A New Tool for HIV Prevention
  - HIV in the United States

Video & Audio: CDC HIV PrEP Guidelines

You may download/link the following options of broadcast quality video and audio featuring NCHHSTP Director Jonathan Mermin, MD, MPH, talking about the new clinical guidelines that recommend health care providers consider pre-exposure prophylaxis (PrEP) for patients at substantial risk for HIV. Please note that these resources are for media use/reprint. If you are a member of the general public and seek additional information about HIV, please visit www.cdc.gov/hiv. If you have additional questions, please call 1(800) CDC INFO or email cdcinfo@cdc.gov.